Table 1.
Clinical data, histology and molecular genetic status, imaging response, and survival
| ID | Age (y) | Histologya WHO II | Extent of surgery | IDH1a | LOH 1p19qa | MGMTa | TMZ dose (mg) | PETb | MRIb | PFS (mo) | OS (mo) | Histologyc (WHO grade) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 37 | A | b | mut | no | – | 20'580 | R (−70) | MR (−31) | 27 | 31 | n.d. |
| 2 | 49 | A | p | – | – | – | 67'620 | R (−56) | SD (−4) | 24 | 31 | n.d. |
| 3 | 35 | A | p | mut | no | m | 29'400 | R (−21) | MR (−25) | 38 | 75 | n.d. |
| 4 | 23 | A | b | wt | no | m | 70'560 | R (−94) | SD (−9) | 19 | 21 | GBM (IV) |
| 5 | 38 | A | b | wt | no | u | 26'880 | n.a.v. | SD (−1) | 40 | 61 | GBM (IV) |
| 6 | 32 | A | p | mut | no | u | 20'160 | NR (+354) | SD (+18) | 13 | 99+ | A (II) |
| 7 | 33 | OA | p | mut | no | – | 45'360 | n.a.v. | PD (+29) | 16 | 27+ | n.d. |
| 8 | 38 | OA | p | mut | yes | m | 61'740 | R (−73) | MR (−40) | 34 | 51+ | n.d. |
| 9 | 28 | OA | p | mut | no | m | 30'500 | R (−94) | MR (−39) | 66 | 119+ | OA (II) |
| 10 | 27 | OA | p | mut | yes | m | 81'600 | R (−69) | SD (−10) | 20 | 44 | AA (III) |
| 11 | 20 | OA | b | mut | no | m | 23'100 | NR (−8) | SD (+0) | 6 | 61+ | OA (II) |
| 12 | 31 | OA | p | mut | no | m | 58'100 | R (−99) | SD (−21) | 73 | 125+ | n.d. |
| 13 | 40 | OA | b | wt | no | u | 53'200 | NR (−6) | SD (−20) | 66 | 139+ | n.d. |
| 14 | 45 | O | b | – | – | – | 37'800 | R (−12) | PR (−67) | 45 | LFU | n.d. |
| 15 | 29 | O | gt | – | – | – | 24'500 | R (−91) | MR (−48) | 17+ | 17+ | n.d. |
| 16 | 41 | O | gt | – | – | – | 10'780 | R (−62) | MR (−34) | 28 | 63+ | O (III) |
| 17 | 43 | O | gt | – | – | – | 8'250 | R (−98) | SD (−4) | 61+ | 61+ | n.d. |
| 18 | 36 | O | b | – | – | – | 13'000 | R (−29) | SD (+2) | 6 | 28+ | n.d. |
| 19 | 41 | O | b | – | – | – | 37'080 | NR (+116) | SD (+3) | 24 | 44+ | n.d. |
| 20 | 40 | O | gt | mut | yes | m | 43'900 | R (−82) | PR (−76) | 61 | 67+ | n.d. |
| 21 | 34 | O | b | mut | yes | m | 36'960 | R (−65) | PR (−61) | 84 | 118+ | n.d. |
| 22 | 44 | O | p | mut | yes | m | 43'680 | R (−91) | PR (−57) | 81+ | 81+ | n.d. |
| 23 | 34 | O | gt | mut | yes | m | 29'820 | R (−98) | PR (−53) | 66+ | 66+ | n.d. |
| 24 | 51 | O | p | wt | no | m | 17'640 | R (−64) | MR (−42) | 23 | 53 | n.d. |
| 25 | 38 | O | p | mut | yes | m | 17'640 | R (−72) | MR (−40) | 36 | 61+ | n.d. |
| 26 | 45 | O | p | mut | yes | m | 26'420 | R (−67) | SD (−8) | 10 | 68+ | n.d. |
| 27 | 37 | O | p | mut | no | m | 24'000 | R (−37) | SD (+1) | 7 | 74+ | O (III) |
| 28 | 51 | O | p | mut | yes | m | 108'000 | n.a.v. | SD (+2) | 47+ | 47+ | n.d. |
| 29 | 43 | O | gt | mut | yes | m | 85'600 | NR (−6) | SD (+5) | 6 | 8+ | n.d. |
| 30 | 53 | O | p | mut | yes | m | 42'300 | R (−56) | SD (+6) | 52+ | 52+ | n.d. |
| 31 | 29 | O | p | mut | yes | m | 37'800 | R (−59) | MR (−42) | 72+ | 72+ | n.d. |
| 32 | 39 | O | p | mut | no | m | 12'750 | R (−27) | SD (−19) | 47 | 73+ | O (II) |
| 33 | 34 | O | p | mut | yes | u | 33'500 | R (−79) | SD (+9) | 16 | 57+ | n.d. |
Abbreviations:
Histologya WHO grade II: A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; AA, anaplastic astrocytoma; n.d., not done.
Extent of surgery: b, biopsy; gt, gross total resection; p, partial resection.
IDH1, isocitrate dehydrogenase 1; mut, mutated; wt, wild type; –, no tissue available.
LOH, co-deletion on chromosomal arms 1p and 19q; no, absent; yes, present; –, no tissue available.
MGMT, O6-methylguanine-DNA methyltransferase; m, methylated; u, unmethylated; –, no tissue available.
PET: n.a.v., no active tumor volume; NR, nonresponder; R, responder.
MRI (RANO): MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease.
PFS, progression-free survival; +, progression-free at end of follow-up.
OS, overall survival; LFU, lost during follow-up; +, alive at end of follow-up.
Histologyc (WHO grade): AA, anaplastic astrocytoma; A, astrocytoma; GBM, glioblastoma; n.d., not done; O, oligodendroglioma; OA, oligoastrocytoma.
alast operation before start of chemotherapy.
bnumber in bracket = maximal volume decrease (−) or increase (+) in percent from baseline.
cafter progression following chemotherapy.